Copyright
©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2007; 13(46): 6150-6155
Published online Dec 14, 2007. doi: 10.3748/wjg.v13.i46.6150
Published online Dec 14, 2007. doi: 10.3748/wjg.v13.i46.6150
Table 2 Efficacy at 1 yr against virological suppression at 24 wk in HBeAg positive and negative individuals in the Globe study
Virological suppression at wk 24 (%) | ||||
< 300copies/mL | 300-1000copies/mL | > 1000-10 000copies/mL | > 10 000copies/mL | |
HBeAg positive patients (wk 52) | ||||
HBV DNA (< 300 copies/mL) | 90 | 70 | 30 | 5 |
ALT normalization | 90 | 89 | 80 | 54 |
Viral breakthrough | 1 | 3 | 8 | 11 |
HBeAg negative patients (wk 52) | ||||
HBV DNA (< 300 copies/mL) | 93 | 66 | 38 | 10 |
ALT normalization | 83 | 74 | 63 | 36 |
Viral breakthrough | 0 | 9 | 18 | 32 |
- Citation: Amarapurkar DN. Telbivudine: A new treatment for chronic hepatitis B. World J Gastroenterol 2007; 13(46): 6150-6155
- URL: https://www.wjgnet.com/1007-9327/full/v13/i46/6150.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i46.6150